ADRB2 and neoplasm: The first evidence on β-ARs’ role in tumor growth came from Schuller et al.’s studies [178], where they revealed that a non-selective β-AR agonist, isoprenaline, induced the lung adenocarcinoma cells’ proliferation, while propranolol counteracted this effect.